Company news

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) news

Ionis Pharmaceuticals, Inc. news releases on 6ix. Latest, Sep 23, 2026: Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study…

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) news

Press releases & updates

Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN)

Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS

Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)

ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients

Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026

Ionis announces Dr. Frank Bennett, chief scientific officer, to retire

Ionis reports second quarter 2026 financial results and highlights progress on key programs

Ionis to hold second quarter 2026 financial results webcast

Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease

Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome

Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy

Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome

Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S.

Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors

Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses

Ionis to host 2026 virtual Annual Meeting of Stockholders

Ionis reports first quarter 2026 financial results and highlights progress on key programs

Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B

Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting

Ionis to hold first quarter 2026 financial results webcast

Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review

Ionis announces changes to Board of Directors

Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting

Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)

Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs

Ionis updates time for fourth quarter and full year 2025 financial results webcast

Ionis to hold fourth quarter and full year 2025 financial results webcast

DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)

Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts

Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B

Ionis to present at 44th Annual J.P. Morgan Healthcare Conference

Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)

Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)

DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)

Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes

Ionis to present at upcoming investor conferences

Ionis Announces Proposed Convertible Offering to Refinance 2026 Convertible Notes

Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions

Ionis presents new data demonstrating long-term disease control with DAWNZERA™ (donidalorsen) at ACAAI 2025 Annual Meeting

Ionis reports third quarter 2025 financial results and highlights progress on key programs

Detailed data from the landmark CORE and CORE2 pivotal studies of olezarsen for sHTG to be presented as a late breaker at AHA Scientific Sessions

Ionis ranked #2 Top Employer by Science magazine, recognizing industry-leading scientific innovation and company culture

Ionis CEO Brett P. Monia receives 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society

Ionis to hold third quarter 2025 financial results webcast

Ionis showcases transformational medicines and industry-leading pipeline at Innovation Day

Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease

TRYNGOLZA® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)

Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseases

Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals

Ionis receives U.S. FDA Breakthrough Therapy designation for ION582 in Angelman syndrome